ARGX
Argen X SE
BIOTECHNOLOGY · HEALTHCARE
argenx NV, based in Breda, the Netherlands, is a forward-thinking clinical-stage biotechnology company focused on delivering transformative antibody-based treatments for severe autoimmune diseases, hematological disorders, and various cancers. Leveraging its proprietary technology platform, argenx i...
$830.79
-2.70% ($23.03)
Volume
250,392
52W High
$953.58
52W Low
$631.47
Market Cap
$54.23B
What to Watch This Quarter
Based on historical dataConsensus EPS
$7.47
Whisper EPS
$8.29
11.0% above consensus
Last Quarter
$7.32
Current Streak
8 Beats
Avg Surprise (4Q)
+21.16%
Next Earnings Report
Reports in 78 days
Price Chart
EPS History: Consensus vs Actual
Last 12 quartersPrice Movement Around Earnings
Q2 2026
Jul 23, 2026
1-Day:
-0.69%
5-Day:
-5.66%
Q1 2026
May 7, 2026
1-Day:
-0.65%
5-Day:
+3.24%
Q4 2025
Feb 26, 2026
1-Day:
-0.60%
5-Day:
-2.96%
Q3 2025
Oct 30, 2025
1-Day:
-0.23%
5-Day:
+1.36%
Revenue & Financial Performance
Revenue Whisper
$3.03B
TWN Proprietary Estimate
Last Quarter Revenue
$1.52B
+59.8% YoY
Gross Margin
168.3%
Net Margin: 55.4%
| Quarter | Revenue | YoY Growth | Gross Margin | Op Margin | Net Income |
|---|---|---|---|---|---|
| Q2'26 | $1.52B | +59.8% | 168.3% | 32.6% | $838.8M |
| Q1'26 | $1.30B | +64.2% | 90.7% | 30.4% | $366.0M |
| Q4'25 | $3.21B | +138.1% | 89.4% | 26.5% | $1.05B |
| Q3'25 | $1.13B | +96.6% | 90.3% | 31.1% | $344.3M |
| Q2'25 | $948.0M | +5.1% | 88.3% | 21.5% | $245.4M |
| Q1'25 | $790.7M | +97.2% | 89.8% | 17.9% | $169.5M |
| Q4'24 | $1.35B | +77.7% | 50.6% | 8.7% | $865.6M |
| Q3'24 | $573.2M | +73.8% | 89.7% | 2.5% | $91.4M |
Company Information
Symbol
ARGX
Company
Argen X SE
Market Cap
$54.23B
Sector
HEALTHCARE
Next Earnings
Oct 22, 2026
Also Reporting Soon
Companies reporting earnings around the same time as ARGX
HEALTHCARE Stocks
Other healthcare companies with earnings data
More in BIOTECHNOLOGY
Compare ARGX with competitors
Side-by-side earnings comparison